Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | GAK | O14976 | 1/20 | 0.30 |
| ▸ | NPM1 | P06748 | 1/20 | 0.30 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20090078 | 0.96 | METAP2 (0.31) | METAP2NPM1ALK | |
| SCHEMBL20090126 | 0.91 | KDM4E (0.32) | KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL20090083 | 0.90 | — | — | |
| SCHEMBL20090138 | 0.87 | PTGES (0.33) | KDM4EALDH1A1HPGDNPM1ALK | |
| SCHEMBL20090082 | 0.86 | NPC1 (0.30) | MAPTMETAP2SMN1; SMN2 | |
| SCHEMBL20090096 | 0.86 | PTGES (0.31) | METAP2 | |
| SCHEMBL20090229 | 0.84 | MAPK8 (0.33) | CYP2C9KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL20090109 | 0.84 | PTGES (0.33) | — | |
| SCHEMBL19960187 | 0.83 | MAPT (0.32) | CYP2C9KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL20090092 | 0.83 | ALDH1A1 (0.34) | CYP2C9KDM4EALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10355225-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
| US-20180114923-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-04-26 | — | — | US | disclosed |
| US-20180114923-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180114923-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, PER2 | CYP2C9 143/4885KDM4E 1997/4885ALDH1A1 750/4885 |
| US-10355225-B2 | Heterocyclic compound and organic light emitting element comprising same | CRY1, CRY2, PER2 | CYP2C9 143/4885KDM4E 1997/4885ALDH1A1 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.